Liquid Biopsy and Machine Learning for Early Colorectal Cancer, Adenomas, Lynch Cancers, and Residual Disease Detection

This study is developing and validating a blood test called liquid biopsy — which detects cancer-related DNA fragments in the bloodstream — combined with machine learning (AI) to detect colorectal cancer, pre-cancerous polyps (adenomas), Lynch syndrome-related cancers, and residual cancer after treatment, earlier and more accurately than current methods. **You may be eligible if:** - You have had a colonoscopy around the time your blood sample is being taken - You have received standard diagnostic procedures and had at least one blood sample collected before any cancer treatment began - You have received standard pathological testing and have been assigned to a diagnostic group in the study **You may NOT be eligible if:** - You are unable or unwilling to provide informed consent - You have inflammatory bowel disease (such as Crohn's disease or ulcerative colitis) Talk to your doctor to see if this trial is right for you.